期刊文献+

易损血液与动脉粥样硬化症关系研究进展 被引量:5

Progression of Relationship Between Susceptible Blood and Atherosclerosis
下载PDF
导出
摘要 研究表明动脉粥样硬化是在内皮损伤、脂质代谢异常、血流动力学损伤、遗传、感染、物理化学等损伤刺激下启动的,多种炎症因子、免疫机制及相关细胞因子网络交叉样作用于血管壁,动脉粥样硬化逐渐形成和发展同时伴随不稳定斑块的破裂、血栓形成,导致慢性和急性缺血或闭塞性临床事件。不论何种机制,血管壁动脉粥样硬化必须通过血液来介导和促进,易损血液包括血液的成分和状态异常,血液易损程度与动脉粥样硬化性临床事件正相关。 Under the stimulation of endothelium injury, abnormality of lipid metabolism, hemodynamic injury, heredity, inflammation and physical chemistry, athcrosclerosis of blood vessel can be informed by the effects of many kinds of inflamintory factors, immunologic meehnism and cytokines. Thrombogenesis of the unstable atheroslerosis results in ischemic or obstructive clinical incidents. Regardless of any mechanisms, atherosclerosis of vessel wall must be mediated by susceptible blood. Susceptible blood includes components and state abnor- mality. There is a positive correlation between susceptible degree of blood and atherosclerotic clinical incidents.
作者 褚现明 安毅
出处 《心血管病学进展》 CAS 2009年第5期867-871,共5页 Advances in Cardiovascular Diseases
关键词 易损血液 动脉粥样硬化 机制 治疗 susceptible blood atherosclerosis mechanism therapy
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献343

同被引文献62

引证文献5

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部